. 2022 Dec 1;9(2):197–205. doi: 10.1001/jamaoncol.2022.5610

Table. Confirmed Intracranial Responses in Patients With Active Brain Metastases and Measurable Intracranial Lesions at Baseline.

Intracranial response	Tucatinib combination (n = 55)^a	Placebo combination (n = 20)^b
Patients with objective response of confirmed complete response or partial response, No.	26	4
Confirmed ORR-IC, % (95% CI)	47.3 (33.7-61.2)	20.0 (5.7-43.7)
DOR-IC, median (95% CI), mo^c	8.6 (5.5-10.3)	3.0 (3.0-10.3)

Abbreviations: DOR-IC, duration of intracranial response; ORR-IC, intracranial objective response rate.

^{^a}

Tucatinib, trastuzumab, and capecitabine.

^{^b}

Placebo, trastuzumab, and capecitabine.

^{^c}

Calculated with the complementary log-log transformation method.